Document:

<PAGE>
                                                                   EXHIBIT 10.25

                               Licence agreement

THIS AGREEMENT dated 11th March 1999 is between:

(1)   UNIVERSITY COLLEGE LONDON, incorporated in the United Kingdom by Royal
      Charter, acting through its Royal Free and University College Medical
      School, whose address is Rowland Hill Street, London NW3 2PF ("Royal
      Free"); and

(2)   BIOENVISION, INC, incorporated in Delaware whose principal place of
      business is at Trafalgar House, 11 Waterloo Place, St James's, London SW
      1Y 4AU] ("Bioenvision").

RECITALS:

A.    Royal Free is the registered owner of Patents (as defined below) and has
      developed technical information ("Know-how", as defined below) relating to
      the development and uses of an eukaryotic gene expression cassette with
      muscle element promotors and related technologies.

B.    Bioenvision recognises that Royal Free owns inventions and intellectual
      property useful in the conduct of Bioenvision's business.

C.    Bioenvision also recognises that its anticipate business activity will
      encompass the practice of technology that requires a license under patents
      owned by Royal Free.

D.    Bioenvision wishes to acquire rights under the Patents and to use the
      Know-how for the development and commercialisation of Licensed Products in
      the Field and in the Territory, in accordance with the provisions of this
      Agreement.

IT IS AGREED as follows:

1 Definitions

In this Agreement, the following words shall have the following meanings:

Affiliate           In relation to a Party, means any entity or person which
                    controls, is controlled by, or is under common control with
                    that Party. For the purposes of this definition, "control"
                    shall mean direct or indirect beneficial ownership of 50%
                    (or, outside a Party's home territory, such lesser
                    percentage as is the maximum, permitted level of foreign
                    investment) or more of the share capital, stock or other
                    participating interest carrying the right to vote or to
                    distribution of profits of that entity or person, as the
                    case may be.

Commencement Date   The date of signature of this agreement (subject to the
                    terms of clause 2.1).

Delivered Items     Has the meaning given in Clause 3.2.

Field               means, and is limited to, the practice of the Invention and
                    Know-how embodied in the patent application referred to in
                    Schedule 1 and licensed hereunder for the treatment of
                    disorders associated with liver dysfunction, disease
                    conditions characterised by decreased production of liver
                    proteins e.g. albumin, cancer, and endocrine disorders that
                    may affect liver function in human and animal applications.

                                  Page 1 of 20

<PAGE>

Know-how            Technical information in the Field:

                    (a)   Developed in the Laboratory under the supervision of
                          the Principal Investigator prior to the
                          Commencement Date and relating directly to the
                          inventions claimed in the Patents; or

                    (b)   Developed in the course of the Project (i) in the
                          Laboratory under the supervision of the Principal
                          Investigator or (ii) by Bioenvision.

Laboratory          The laboratory of the Principal Investigator within Royal
                    Free's Department of Anatomy and Developmental Biology.

Licensed Products   Any and all products that are manufactured, sold or
                    otherwise supplied by Bioenvision or its sub-licensees and
                    which (a) are within any Valid Claim of the Patents and/or
                    (b) incorporate, or their development made use of, any of
                    the Know-how.

Net Receipts        The amounts received by Bioenvision or its Affiliates
                    from the grant of sub-licences under the Patents and
                    Know-how, less any Value Added Tax or other sales tax.

Net Sales Value     The invoiced price of Licensed Products sold by Bioenvision
                    or its Affiliates to independent third parties in arm's
                    length transactions exclusively for money or, where the sale
                    is not at arm's length, the price that would have been so
                    invoiced if it had been at arm's length, after deduction of
                    normal trade discounts actually granted and any credits
                    actually given, and, provided the amounts are separately
                    charged on the relevant invoice any costs of packaging,
                    insurance, carriage and freight, any value added tax or
                    other sales tax, and any import duties or similar applicable
                    government levies.

Parties             Royal Free and Bioenvision, and "Party" shall mean either of
                    them.

Patents             Any and all of the patents and patent applications referred
                    to in Schedule 1, and any and all of the patents and patent
                    applications (if any) which may be made during the term of
                    this Agreement and which form part of the Project IPR,
                    including any continuations, continuations in part,
                    extensions, reissues, divisions, and any patents,
                    supplementary protection certificates and similar rights
                    that are based on or derive priority from the foregoing.

Principal
Investigator        Professor Geoffrey Goldspink

                                  Page 2 of 20
<PAGE>

Project             The further development by the Parties of the inventions and
                    developments described in the Patents and the Know-how. The
                    Parties anticipate that the Project shall be conducted in
                    accordance with the provisions of Schedule 3.

Project IPR         Any and all inventions, know-how, data and other
                    developments made in the course of the Project, and any
                    patent applications, patents and other intellectual property
                    that may be generated in respect of such inventions,
                    know-how, data and developments during the term of this
                    Agreement.

Territory           European Community, United States of America, Canada, Middle
                    East, Japan.

Valid Claim         A claim of a patent or patent application that has not
                    expired or been held invalid or unenforceable by a court of
                    competent jurisdiction in a final and non-appealable
                    judgment.

2     Grant of rights

2.1   The parties agree to execute a Co-development agreement for the pursuit of
      the Project to be executed within 30 days (or some other period agreed
      between the parties) of the Commencement Date. If such a Co-development is
      not executed, then this License Agreement will terminate.

2.1.1    Licences. Royal Free hereby grants to Bioenvision, subject to the
         provisions of this Agreement:

2.1.2    an exclusive licence in the Field under the Patents, with the right to
         sub-license, subject to clause 2.3 below, to develop, manufacture, have
         manufactured, use and sell Licensed Products but only in the Field in
         the Territory; and

2.1.3    an exclusive licence in the Field to use the Know-how, with the right
         to sub-license, subject to clause 2.3 below, to develop, manufacture,
         have manufactured, use and sell Licensed Products but only in the Field
         in the Territory.

2.2   Formal licences. The Parties shall execute such formal licences as may be
      necessary or appropriate for registration with Patent Offices and other
      relevant authorities in particular territories. In the event of any
      conflict in meaning between any such licence and the provisions of this
      Agreement, the provisions of this Agreement shall prevail wherever
      possible. Prior to the execution of the formal licence(s) (if any)
      referred to above, the Parties shall so far as possible have the same
      rights and obligations towards one another as if such licence(s) had been
      granted. The Parties shall use reasonable endeavours to ensure that, to
      the extent permitted by relevant authorities, this Agreement shall not
      form part of any public record.

2.3   Sub-licensing. Bioenvision shall be entitled to grant sub-licences of its
      rights under this Agreement to any person, provided that:

                                  Page 3 of 20
<PAGE>

2.3.1    the royalties and other consideration provided for in the sub-licence
         shall be at an amount or rate which is not less than the amount or rate
         provided for in this Agreement;

2.3.2    the sub-licence shall include obligations on the sub-licensee which are
         equivalent to the obligations on Bioenvision under this Agreement;

2.3.3    the sub-licence shall terminate automatically on the termination of
         this Agreement for any reason;

2.3.4    within 30 days of the grant of any sub-licence Bioenvision shall
         provide to Royal Free a true copy of it; and

2.3.5    Bioenvision shall be responsible for any breach of the sub-licence by
         the sub-licensee, as if the breach had been that of Bioenvision under
         this Agreement, and Bioenvision shall indemnify Royal Free against any
         loss, damages, costs, claims or expenses which are awarded against or
         suffered by Royal Free as a result of any such breach by the
         sub-licensee.

2.4   Reservation of rights. Royal Free reserves the non-exclusive right to use
      the Know-how and the Patents in the Field for the purposes of academic
      research and teaching. Royal Free shall have the exclusive, worldwide,
      sub-licensable right to use, develop and commercialise Project IPR outside
      the Field.

2.5   No other licence. It is acknowledged and agreed that no licence is granted
      by Royal Free to Bioenvision other than the licence(s) expressly granted
      by the provisions of this clause 2. Without prejudice to the generality of
      the foregoing Royal Free reserves all rights under the Patents and
      Know-how outside the Field.

2.6   Quality. Bioenvision shall ensure that all of the Licensed Products
      marketed by it and its sub-licensees are of satisfactory quality and
      comply with all applicable laws and regulations in each part of the
      Territory.

3     Know-how and Confidential Information

3.1   Provision of Know-how. Upon Bioenvision's reasonable request, Royal Free
shall arrange for the Principal Investigator to supply Bioenvision with all
Know-how in his possession that Royal Free is at liberty to disclose and has not
previously been disclosed and which is reasonable necessary or desirable to
enable Bioenvision to undertake the further development of the Licensed
Products. The Know-how shall be subject to the confidentiality provisions of
Clause 3.5. The method of such supply shall be agreed between the Principal
Investigator and Bioenvision but shall not require the Principal Investigator to
undertake more than 2 man-days of work, unless otherwise agreed in writing
between the Parties. If it is agreed that the Principal Investigator shall
travel to Bioenvision's premises in connection with such supply, Bioenvision
shall reimburse all reasonable travel, accommodation and subsistence costs
incurred.

3.1   Status of Know-how. Bioenvision acknowledges that the Know-how is at an
      early stage of development. Accordingly, specific results cannot be
      guaranteed and any results, materials, information or other items,
      including without limitation Know-how (together "Delivered Items")
      provided under or in connection with this Agreement are provided "as is"
      and without any express or implied warranties, representations or
      undertakings. As examples, but without limiting the foregoing, Royal Free
      does not give any warranty that Delivered Items are of merchantable or
      satisfactory quality, are fit for any particular purpose, comply with any
      sample or description, or are viable, uncontaminated, safe or non-toxic.

                                  Page 4 of 20
<PAGE>

3.2   Responsibility for development of Licensed Products. Bioenvision shall be
      exclusively responsible for the technical and commercial development and
      manufacture of Licensed Products and for incorporating any modifications
      or developments thereto that may be necessary or desirable and for all
      Licensed Products sold or supplied, and accordingly Bioenvision shall
      indemnify Royal Free in the terms of Clause 7.3.

3.3   Use of Know-how. Bioenvision undertakes that for a period of 10 years from
      the Commencement Date or for so long as any substantial part of the
      Know-how remains subject to the obligations of confidence of Clause 3.5,
      whichever is the shorter, it will not use the Know-how for any purpose
      except as expressly licensed hereby and in accordance with the provisions
      of this Agreement.

3.4   Confidentiality obligations. Each Party ("Receiving Party") undertakes:

3.4.1    to maintain as secret and confidential all Know-how and other technical
         or commercial information obtained directly or indirectly from the
         other Party ("Disclosing Party") in the course of or in anticipation of
         this Agreement and to respect the Disclosing Party's rights therein,

3.4.2    to use the same exclusively for the purposes of this Agreement, and

3.4.3    to disclose the same only to those of its employees, contractors and
         sub-licensees pursuant to this Agreement (if any) to whom and to the
         extent that such disclosure is reasonably necessary for the purposes of
         this Agreement.

3.5   Exceptions to obligations. The provisions of Clause 3.5 shall not apply to
      Know-how and other information which the Receiving Party can demonstrate
      by reasonable, written evidence:

3.5.1    was, prior to its receipt by the Receiving Party from the Disclosing
         Party, in the possession of the Receiving Party and at its free
         disposal; or

3.5.2    is subsequently disclosed to the Receiving Party without any
         obligations of confidence by a third party who has not derived it
         directly or indirectly from the Disclosing Party; or

3.5.3    is or becomes generally available to the public through no act or
         default of the Receiving Party or its agents, employees, Affiliates or
         sub-licensees; or

3.5.4    the Receiving Party is required to disclose to the courts of any
         competent jurisdiction, or to any government regulatory agency or
         financial authority, provided that the Receiving Party shall (i) inform
         the Disclosing Party as soon as is reasonably practicable, and (ii) at
         the Disclosing Party's request seek to persuade the court, agency or
         authority to have the information treated in a confidential manner,
         where this is possible under the court, agency or authority's
         procedures; or

                                  Page 5 of 20
<PAGE>

3.5.5    in the case of information disclosed by Royal Free to Bioenvision, is
         disclosed to actual or potential customers for Licensed Products in so
         far as such disclosure is reasonably necessary to promote the sale or
         use of Licensed Products, provided that the customers sign a written
         confidentiality undertaking at least as restrictive as Clauses 3.5 and
         3.6.

3.6   Disclosure to employees. The Receiving Party shall procure that all of its
      employees, contractors and sub-licensees pursuant to this Agreement (if
      any) who have access to any of the Disclosing Party's information to which
      Clause 3.5 applies, shall be made aware of and subject to these
      obligations and shall have entered into written undertakings of
      confidentiality at least as restrictive as Clauses 3.5 and 3.6 and which
      apply to the Disclosing Party's information.

3.7   The fact that some or all of the Know-how becomes public knowledge shall
      not affect the financial obligations for use of the Know-how licensed
      under this Agreement if such Know-how was used or usable in the discovery,
      development, manufacture, or approval for sale of Licensed Products within
      the Field.

4     Payments

4.1   Payments for development work and clinical trials.

4.1.1    Bioenvision shall pay the costs of any further pre-clinical development
         work deemed necessary prior to commencing clinical trials for the
         Project, and this shall include the development of Licensed Products
         for other therapeutic applications, the use of different formulations
         and preparations of Licensed Products.

4.1.2    Bioenvision shall pay the costs of clinical trials of Licensed
         Products. The costs of such development will not exceed $3 million
         (three million U.S. dollars).

4.1.3    Bioenvision shall pay the cost of prosecuting, filing and maintaining
         patents and defending revocation proceedings on patents and patent
         applications, on the Licensed Products within the Territory that shall
         become due after the date of this Agreement.

4.1.4    Bioenvision shall pay to Royal Free a milestone payment of
         (pound)200,000 in addition to any royalty or other payments on
         successful completion of the first Phase III trial for the first of
         the Licensed Products developed under this Agreement.

4.2   Initial payment. Within 30 days of the Commencement Date, the Bioenvision
      shall pay to Royal Free the non-refundable, sum of (pound)20,000 (pounds
      sterling) which shall be the first instalment of the monies due under
      Clause 4.1 (a)

4.3   Royalties. Bioenvision shall pay to Royal Free a royalty being a
      percentage of the Net Sales Value of all Licensed Products or any part
      thereof sold by Bioenvision or its sub-licensees. The percentage shall be
      the higher of the following alternative percentages which applies to the
      Licensed Product in question:

4.3.1    6 per cent in the case of Licensed Products which are within a Valid
         Claim of a Patent in the country of manufacture or sale; or

                                  Page 6 of 20

<PAGE>

4.3.2    6 per cent in the case of Licensed Products which incorporate, or whose
         development made use of, any of the Know-how.

4.4   Combination Products. If any Licensed Products are incorporated in any
      other product ("Combination Product") supplied by the Bioenvision or its
      sub-licensees and the Licensed Product is not priced separately from the
      Combination Product, the Net Sales Value of such Licensed Product shall be
      deemed to be that proportion of the Net Sales Value of the Combination
      Product which is attributable to the Licensed Product, comparing the
      manufacturing cost of the Licensed Product with that of the Combination
      Product, as in the following formula: Net Sales Value of Licensed Product
      = (manufacturing cost of Licensed Product divided by total manufacturing
      cost of Combination Product) x Net Sales Value of Combination Product.]

4.5   Minimum royalties. If the royalties payable under Clause 4.3 are less than
      $3,000 (USD) ("Minimum Royalty") in any calendar year after year three of
      this agreement, Bioenvision shall pay to Royal Free the amount by which
      the said royalties are less than the Minimum Royalty within 60 days of the
      end of such calendar year, failing which Royal Free shall be entitled to
      terminate this Agreement and all licences granted under this Agreement by
      notice in writing to the Bioenvision given at any time after the expiry of
      the said 60 day period. If this Agreement ends on any day other than the
      end of a calendar year (ie December 31st), the Minimum Royalty due for
      that year shall be reduced, pro-rata, ie the minimum amount due shall be
      the Minimum Royalty for a complete year multiplied by the number of days
      of the final calendar year during which this Agreement was in force, and
      divided by 365 days.

4.6   Third party royalties. If, during the continuation of this Agreement,
      Bioenvision considers it necessary to obtain a licence from any third
      party ("Third Party Licence") in order to avoid infringing such third
      party's patent(s) in the course of manufacture or sale of Licensed
      Products, the royalties payable under this Agreement shall be reduced by
      the amount of royalties paid under the Third Party Licence provided that
      the amount of royalty payable by Bioenvision to Royal Free in any
      quarterly period shall not be reduced by more than 50% of the amount which
      would have been payable in the absence of this clause 4.6.

4.7   Payment dates.

4.7.1    Royalties due under this Agreement shall be paid within 60 days of the
         end of each quarter ending on 31 March, 30 June, 30 September and 31
         December, in respect of sales of Licensed Products made during such
         quarter and within 60 days of the termination of this Agreement;

4.7.2    If this Agreement is for any reason terminated before all the earned
         royalties herein provided for have been paid, Bioenvision shall
         immediately pay to Royal Free any remaining unpaid balance of earned
         royalties even though the due date provided in Clause 4.2 has not been
         reached.

4.8   Payment terms. All sums due under this Agreement:-

4.8.1    are exclusive of Value Added Tax which where applicable will be paid by
         Bioenvision to Royal Free in addition;

                                  Page 7 of 20
<PAGE>

4.8.2    shall be paid in pounds sterling by irrevocable, confirmed letter of
         credit drawn on a London bank, and in the case of sales or sub-license
         income received by Bioenvision in a currency other than pounds
         sterling, the royalty shall be calculated in the other currency and
         then converted into equivalent pounds sterling at the buying rate of
         such other currency as quoted by Barclays Bank plc in London as at the
         close of business on the last business day of the quarterly period with
         respect to which the payment is made;

4.8.3    shall be made without deduction of income tax or other taxes charges or
         duties that may be imposed, except insofar as Bioenvision is required
         to deduct the same to comply with applicable laws. The Parties shall
         cooperate and take all steps reasonably and lawfully available to them,
         at the expense of Royal Free, to avoid deducting such taxes and to
         obtain double taxation relief. If Bioenvision is required to make any
         such deduction it shall provide Royal Free with such certificates or
         other documents as it can reasonably obtain to enable Royal Free to
         obtain appropriate relief from double taxation of the payment in
         question; and

4.8.4    shall be made by the due date, failing which Royal Free may charge
         interest on any outstanding amount on a daily basis at a rate
         equivalent to 3% above the Bank of England base lending rate then in
         force.

4.9   Exchange controls, etc. If at any time during the continuation of this
      Agreement Bioenvision is prohibited from making any of the payments
      required hereunder by a governmental authority in any country then
      Bioenvision will within the prescribed period for making the said payments
      in the appropriate manner use its best endeavours to secure from the
      proper authority in the relevant country permission to make the said
      payments and will make them within 7 days of receiving such permission. If
      such permission is not received within 30 (thirty) days of Bioenvision
      making a request for such permission then, at the option of Royal Free,
      Bioenvision shall deposit the royalty payments due in the currency of the
      relevant country either in a bank account designated by Royal Free within
      such country or such royalty payments shall be made to an associated
      company of Royal Free designated by Royal Free and having offices in the
      relevant country designated by Royal Free.

4.10  Royalty statements. Bioenvision shall send to Royal Free at the same time
      as each royalty payment is made in accordance with clause 4.3 a statement
      setting out, in respect of each territory or region in which Licensed
      Products are sold, the types of Licensed Product sold, the quantity of
      each type sold, and the total Net Sales Value in respect of each type,
      expressed both in local currency and pounds sterling and showing the
      conversion rates used, during the period to which the royalty payment
      relates.

4.11  Records

4.11.1   Bioenvision shall keep at its normal place of business detailed and up
         to date records and accounts showing the quantity, description and
         value of Licensed Products sold by it, and the amount of sublicensing
         revenues received by it in respect of Licensed Products, on a country
         by country basis, and being sufficient to ascertain the royalties due
         under this Agreement.

                                  Page 8 of 20
<PAGE>

4.11.2   Bioenvision shall make such records and accounts available, on
         reasonable notice, for inspection during business hours by an
         independent chartered accountant nominated by Royal Free for the
         purpose of verifying the accuracy of any statement or report given by
         Bioenvision to Royal Free under this Clause 4. The accountant shall be
         required to keep confidential all information learnt during any such
         inspection, and to disclose to Royal Free only such details as may be
         necessary to report on the accuracy of Bioenvision's statement or
         report. Royal Free shall be responsible for the accountant's charges
         unless the accountant certifies that there is an inaccuracy of more
         than 5 per cent in any royalty statement, in which case Bioenvision
         shall pay his charges in respect of that inspection.

4.11.3   Bioenvision shall ensure that Royal Free has the same rights as those
         set out in this Clause 4.12 in respect of any sub-licensee of
         Bioenvision which is sub-licensed under the Patents or Know-how
         pursuant to this Agreement.

5     Commercialisation

5.1   Bioenvision shall diligently proceed to develop and commercially exploit
      Licensed Products to the maximum extent worldwide.

5.2   Without prejudice to the generality of Bioenvision's obligations under
      Clause 5.1, Bioenvision shall provide at least annually to Royal Free an
      updated, written Development Plan, showing all past, current and projected
      activities taken or to be taken by Bioenvision to bring Licensed Products
      to market and maximise the sale of Licensed Products worldwide. Royal
      Free's receipt or approval of any such plan shall not be taken to waive or
      qualify Bioenvision's obligations under Clause 5.1.

5.3   If Royal Free considers at any time during the period of this Agreement
      that Bioenvision has without legitimate reason failed to proceed
      diligently to develop and commercially exploit Licensed Products, Royal
      Free shall be entitled to refer to an independent expert the following
      questions:

5.3.1    whether Bioenvision has acted diligently; and if not

5.3.2    what specific action Bioenvision should have taken ("Specific Action")
         in order to have acted diligently.

5.4   The independent expert shall be appointed in accordance with the
      provisions of Schedule 2 and his decision shall be final and binding on
      the Parties.

5.5   If the expert determines that Bioenvision has failed to comply with its
      obligations, under this Clause 5, and if Bioenvision fails to take the
      Specific Action within 6 months of the expert giving his decision in
      accordance with Schedule 2, Royal Free shall be entitled, by giving, at
      any time within 3 months after the end of that 6 month period, not less
      than 3 months' notice to terminate this Agreement and the licences granted
      to Bioenvision under Clause 2.

6     Intellectual Property

6.1   Obtain and maintain the Patents.

                                  Page 9 of 20
<PAGE>

6.1.1    Bioenvision shall at its own cost and expense:

6.1.1.1  co-operate with Royal Free and its partners outside the Field (if any)
         and endeavour to obtain valid Patents in the Field so as to secure the
         broadest monopoly reasonably available; and

6.1.1.2  pay all renewal fees in respect of the Patents as and when due;

                  provided that if Bioenvision wishes to abandon any such
                  application or not to maintain any such Patent (or to cease
                  funding such application or Patent) it shall give 3 months
                  prior written notice to Royal Free and on the expiry of such
                  notice period Bioenvision shall cease to be licensed under the
                  patent application or patent identified in the notice.

6.1.2    Without prejudice to the provisions of Clause 6.2.(a), the Parties
         agree that all Project IPR shall be jointly owned by the Parties as
         beneficial owners in common, subject to the provisions of this
         Agreement.

6.2   Infringement of the Patents

6.2.1    Each Party shall inform the other Party promptly if it becomes aware of
         any infringement or potential infringement of any of the Patents in the
         Field, and the Parties shall consult with each other to decide the best
         way to respond to such infringement.

6.2.2    If the Parties fail to agree on a joint programme of action, including
         how the costs of any such action are to be borne and how any damages or
         other sums received from such action are to be distributed, then
         Bioenvision shall be entitled to take action against the third party at
         its sole expense and it shall be entitled to all damages or other sums
         received from such action, after reimbursing Royal Free for any
         reasonable expenses incurred in assisting it in such action. Royal Free
         shall agree to be joined in any suit to enforce such rights subject to
         being indemnified and secured in a reasonable manner as to any costs,
         damages, expenses or other liability and shall have the right to be
         separately represented by its own counsel at its own expense. If the
         alleged infringement is both within and outside the Field, the Parties
         shall also co-operate with Royal Free's other partners (if any) in
         relation to any such action.

6.3   Infringement of third party rights

6.3.1    If any warning letter or other notice of infringement is received by a
         Party, or legal suit or other action is brought against a Party,
         alleging infringement of third party rights in the manufacture, use or
         sale of any Licensed Product or use of any Patents, that Party shall
         promptly provide full details to the other Party, and the Parties shall
         discuss the best way to respond.

6.3.2    Bioenvision shall have the right but not the obligation to defend such
         suit and shall have the right to settle with such third party, provided
         that if any action or proposed settlement involves the making of any
         statement, express or implied, concerning the validity of any Patent,
         the consent of Royal Free must be obtained before taking such action or
         making such settlement.

                                 Page 10 of 20
<PAGE>

6.3.3    Royal Free shall have the right to participate and be represented in
         any such claims by a third party by its own legal representation, the
         cost to be borne by Royal Free.

6.3.4    In the event, by way of counterclaim or otherwise, either Party or both
         Parties recover any damages or other sums in any action, suit, or
         proceedings involving a claim by a third party, or in settlement
         thereof, such recovery shall be applied and shared as mutually agreed.

6.4   Revocation proceedings.

6.4.1    In the event either Party becomes aware of the institution by a third
         party of any proceedings for the revocation of any Patent, patents [or
         Improvements] in any country in the Territory licensed hereunder to
         Bioenvision, such Party shall notify the other Party promptly.
         Bioenvision shall defend any such proceedings at its own expense, in
         its own name.

6.4.2    Royal Free shall have the right to participate in such revocation
         proceedings at Bioenvision's expense, and will lend its name to such
         proceedings if requested by Bioenvision or required by law.
         Sub-licensees of Bioenvision shall also have the right to participate
         in such revocation proceedings.

6.4.3    Settlement of any revocation proceedings shall be subject to the
         approval of Royal Free; such approval shall not be unreasonably
         withheld.

7     Warranties and liability

7.1   Warranties by Royal Free. Royal Free warrants, represents and undertakes
      as follows:-

7.1.1    subject to Clause 7.3, it is the absolute and unencumbered owner of the
         Patents and has caused its directors and employees to execute such
         assignments of the Patents as may be necessary to give title to the
         Patents to Royal Free; and

7.1.2    it has not done, and will not do nor agree to do during the
         continuation of this Agreement, any of the following things if to do so
         would be inconsistent with the exercise by Bioenvision of the rights
         granted to it under this Agreement, namely:

7.1.2.1  grant or agree to grant any rights in the Patents or any improvements
         thereto; or

7.1.2.2  assign, mortgage, charge or otherwise transfer any of the Patents or
         (subject to clause 9.3 below) any of its rights or obligations under
         this Agreement.

7.2   No other warranties

7.2.1    Each of Bioenvision and Royal Free acknowledges that, in entering into
         this Agreement, it does not do so in reliance on any representation,
         warranty or other provision except as expressly provided in this
         Agreement, and any conditions, warranties or other terms implied by
         statute or common law are excluded from this Agreement to the fullest
         extent permitted by law.

                                 Page 11 of 20
<PAGE>

7.2.2    Without limiting the scope of Clause 7.2.(a), Royal Free does not give
         any warranty, representation or undertaking:-

7.2.2.1  as to the efficacy or usefulness of the Patents or Know-how; or

7.2.2.2  that any of the Patents is or will be valid or subsisting or (in the
         case of an application) will proceed to grant; or

7.2.2.3  that the use of any of the Patents or Know-how, the manufacture, sale
         or use of the Licensed Products or the exercise of any of the rights
         granted under this Agreement will not infringe any other intellectual
         property or other rights of any other person; or

7.2.2.4  as imposing any obligation on Royal Free to bring or prosecute actions
         or proceedings against third parties for infringement or to defend any
         action or proceedings for revocation of any of the Patents; or

7.2.2.5  as imposing any liability on Royal Free in the event that any third
         party supplies Licensed Products to customers located in the Territory.

7.3   Indemnity.

7.3.1    Bioenvision shall indemnify and hold harmless Royal Free, Royal Free
         and their respective officers, employees, consultants, agents and
         representatives (the "Indemnitees") against all third party Claims
         which may be asserted against or suffered by any of the Indemnitees and
         which relate to:-

         (a)      the use of any Delivered Items, or

         (b)      the manufacture, distribution, sale, supply or use of any
                  Licensed Products or any other products or services which
                  incorporate any Delivered Items,

         by or on behalf of Bioenvision, its Affiliates or sub-licensees, or
         subsequently by any third party, including without limitation claims
         based on product liability laws.

7.4   For the purpose of this clause 7.3, "Claims" shall mean all demands,
      claims and liability (whether criminal or civil, in contract, tort or
      otherwise) for losses, damages, legal costs and other expenses of any
      nature whatsoever, and all costs and expenses incurred in connection
      therewith.

7.5   Liability. Notwithstanding any other provision of this Agreement, no Party
      shall be liable to any other Party to this Agreement in contract, tort,
      negligence, breach of statutory duty or otherwise for any loss, damage,
      costs or expenses of any nature whatsoever incurred or suffered by that
      other party or its Affiliates of an indirect or consequential nature
      including without limitation any economic loss or other loss of turnover,
      profits, business or goodwill.

8     Duration and Termination

8.1   Commencement and Termination by Expiry. This Agreement, and the licences
      granted hereunder, shall come into effect on the Commencement Date and,
      unless terminated earlier in accordance with this Clause 8, shall continue
      in force on a country by country basis until the later of:

                                 Page 12 of 20
<PAGE>

8.1.1    the date on which all the Patents have expired or been revoked without
         a right of further appeal, and

8.1.2    the tenth anniversary of the Commencement Date;

         and on such date this Agreement and the licences granted hereunder
         shall terminate automatically by expiry.

8.2   Early termination

8.2.1    Bioenvision may terminate this Agreement at any time on 90 days notice
         in writing to Royal Free.

8.2.2    Without prejudice to any other right or remedy, either Party may
         terminate this Agreement at any time by notice in writing to the other
         Party ("Other Party"), such notice to take effect as specified in the
         notice:-

8.2.2.1  if the Other Party is in breach of this Agreement and, in the case of a
         breach capable of remedy within 90 days, the breach is not remedied
         within 90 days of the Other Party receiving notice specifying the
         breach and requiring its remedy; or

8.2.2.2  if the Other Party becomes insolvent, or if an order is made or a
         resolution is passed for the winding up of the Other Party (other than
         voluntarily for the purpose of solvent amalgamation or reconstruction),
         or if an administrator, administrative receiver or receiver is
         appointed in respect of the whole or any part of the Other Party's
         assets or business, or if the Other Party makes any composition with
         its creditors or takes or suffers any similar or analogous action in
         consequence of debt.

8.2.3    Royal Free may forthwith terminate this Agreement by giving written
         notice to Bioenvision if Bioenvision or its Affiliate or sub-licensee
         commences legal proceedings, or assists any third party to commence
         legal proceedings, to challenge the validity or ownership of any of the
         Patents.

8.3   Consequences of termination

8.3.1    Upon termination of this Agreement by expiry under clause 8.1 above,
         Bioenvision shall have the non-exclusive right to use the Know-how
         without charge or other obligation to Royal Free.

8.3.2    Upon termination of this Agreement for any reason otherwise than in
         accordance with Clause 8.1:

8.3.2.1  Bioenvision and its sub-licensees shall be entitled to sell, use or
         otherwise dispose of (subject to payment of royalties under clause 4)
         any unsold or unused stocks of the Licensed Products for a period of 6
         months following the date of termination;

                                 Page 13 of 20
<PAGE>

8.3.2.2  subject to paragraph (a) above, Bioenvision shall no longer be licensed
         to use or otherwise exploit in any way, either directly or indirectly,
         the Patents, in so far and for as long as any of the Patents remains in
         force or the Know-how;

8.3.2.3  subject to paragraph (a) above, Bioenvision shall consent to the
         cancellation of any formal licence granted to it, or of any
         registration of it in any register, in relation to any of the Patents;

8.3.2.4  the provisions of certain clauses shall continue in force, to be
         defined; and

8.3.2.5  subject as provided in this Clause 8.3.(b) and 8.3.(c) and 8.3.(d), and
         except in respect of any accrued rights, neither party shall be under
         any further obligation to the other.

8.3.3    Upon termination of this Agreement for any reason otherwise than
         in accordance with Clause 8.1, and at Royal Free' request, the Parties
         shall negotiate in good faith the terms of an agreement between them on
         reasonable commercial terms under which Bioenvision would:

8.3.3.1  transfer to Royal Free exclusively all clinical and other data relating
         to the development of Licensed Products;

8.3.3.2  to the extent possible, seek to have any product licences, pricing
         approvals and other permits and applications transferred into the name
         of Royal Free or its nominee;

8.3.3.3  grant Royal Free an exclusive, worldwide licence, with the rights to
         grant sub-licences, under any improvements and other intellectual
         property owned or controlled by Bioenvision relating to the Licensed
         Products; and

8.3.3.4  grant Royal Free or its nominee the right to continue to use any
         product name that had been applied to the Licensed Products prior to
         termination of this Agreement.

8.3.4    If the Parties are unable to agree the terms of an agreement as
         described in Clause 8.3.(c) within 90 days of Royal Free requesting the
         negotiation of such an agreement, either Party may refer the terms for
         settlement by an independent expert who shall be appointed in
         accordance with the provisions of Schedule 2 and whose decision shall
         be final and binding on the Parties. The Parties shall promptly execute
         an agreement on the terms agreed between them or settled by the expert.

9     General

9.1   Force majeure. Neither Party shall have any liability or be deemed to be
      in breach of this Agreement for any delays or failures in performance of
      this Agreement which result from circumstances beyond the reasonable
      control of that Party, including without limitation labour disputes
      involving that Party. The Party affected by such circumstances shall
      promptly notify the other Party in writing when such circumstances cause a
      delay or failure in performance and when they cease to do so.

9.2   Amendment. This Agreement may only be amended in writing signed by duly
      authorised representatives of Royal Free and Bioenvision.

                                 Page 14 of 20
<PAGE>

9.3   Assignment and third party rights.

9.3.1    Subject to clause 9.3.(b) below, neither Party shall assign, mortgage,
         charge or otherwise transfer any rights or obligations under this
         Agreement, nor any of the Patents or rights under the Patents, without
         the prior written consent of the other Party.

9.3.2    Either Party may assign all its rights and obligations under this
         Agreement together with its rights in the Patents to any company to
         which it transfers all [or part] of its assets or business, PROVIDED
         that the assignee undertakes to the other Party to be bound by and
         perform the obligations of the assignor under this Agreement. However a
         Party shall not have such a right to assign this Agreement if it is
         insolvent or any other circumstance described in Clause 8.2.(b) applies
         to it.

9.4      Waiver. No failure or delay on the part of either Party to exercise any
         right or remedy under this Agreement shall be construed or operate as a
         waiver thereof, nor shall any single or partial exercise of any right
         or remedy preclude the further exercise of such right or remedy.

9.5      Invalid clauses. If any provision or part of this Agreement is held to
         be invalid, amendments to this Agreement may be made by the addition or
         deletion of wording as appropriate to remove the invalid part or
         provision but other wise retain the provision and the other provisions
         of this Agreement to the maximum extent permissible under applicable
         law.

9.6      No Agency. Neither Party shall act or describe itself as the agent of
         the other, nor shall it make or represent that it has authority to make
         any commitments on the other's behalf.

9.7      Interpretation. In this Agreement:

9.7.1    the headings are used for convenience only and shall not affect its
         interpretation;

9.7.2    references to persons shall include incorporated and unincorporated
         persons; references to the singular include the plural and vice versa;
         and references to the masculine include the feminine;

9.7.3    references to Clauses and Schedules mean clauses of, and schedules to,
         this Agreement; and

9.7.4    references to the grant of "exclusive" rights shall mean that the
         person granting the rights shall neither grant the same rights (in the
         same Field and Territory) to any other person, nor exercise those
         rights directly to the extent that and for as long as the Licensed
         Products are within Valid Claims of unexpired Patents.

9.8   Notices

9.8.1    Any notice to be given under this Agreement shall be in writing and
         shall be sent by first class mail or air mail, or by fax (confirmed by
         first class mail or air mail) to the address of the relevant Party set
         out at the head of this Agreement, or to the relevant fax number set
         out below, or such other address or fax number as that Party may from
         time to time notify to the other Party in accordance with this Clause
         9.8. The fax numbers of the Parties are as follows: Royal Free - 44 -
         171 794 3505; Bioenvision - 44 - 171 839 7570

                                  Page 15 of 20
<PAGE>

9.8.2    Notices sent as above shall be deemed to have been received three
         working days after the day of posting (in the case of inland first
         class mail), or seven working days after the date of posting (in the
         case of air mail), or on the next working day after transmission (in
         the case of fax messages, but only if a transmission report is
         generated by the sender's fax machine recording a message from the
         recipient's fax machine, confirming that the fax was sent to the number
         indicated above and confirming that all pages were successfully
         transmitted).

9.9   Law and Jurisdiction. The validity, construction and performance of this
      Agreement shall be governed by English law and shall be subject to the
      exclusive jurisdiction of the English courts to which the parties hereby
      submit, except that a Party may seek an interim injunction in any court of
      competent jurisdiction.

9.10  Further action. Each Party agrees to execute, acknowledge and deliver such
      further instruments, and do all further similar acts, as may be necessary
      or appropriate to carry out the purposes and intent of this Agreement.

9.11  Announcements. Neither Party shall make any press or other public
      announcement concerning any aspect of this Agreement, or make any use of
      the name of the other Party in connection with or in consequence of this
      Agreement, without the prior written consent of the other Party.

9.12  Entire agreement. This Agreement, including its Schedules, sets out the
      entire agreement between the Parties relating to its subject matter and
      supersedes all prior oral or written agreements, arrangements or
      understandings between them relating to such subject matter. The Parties
      acknowledge that they are not relying on any representation, agreement,
      term or condition which is not set out in this Agreement.

AGREED by the parties through their authorised signatories:-

For and on behalf of                             For and on behalf of
UNIVERSITY COLLEGE LONDON                        BIOENVISION, INC

/s/ C. A. TARHAN                                 /s/ C.B. WOOD
---------------------------                      -------------------------------
signed                                           signed

C. A. TARHAN                                     C.B. WOOD
---------------------------                      -------------------------------
print name                                       print name

Finance Director and Head of Adminstration       CEO
------------------------------------------       -------------------------------
Title                                            title

1/3/99                                           24/2/99
---------------------------                      -------------------------------
Date                                             date

                                  Page 16 of 20
<PAGE>

                                   Schedule 1

                                   The Patent

1)    Patent number - (published as) WO 98/49333
               (international application number) - PCT/GB98/01198

Priority date - 25 April 1997

Territories designated - Japan, USA, Europe (all territories)

2)    Patent number - 07/500,375

Derived from PCT/GB 94/01114

Priority date - 20 May 1993

Territory designated - Japan

                                  Page 17 of 20
<PAGE>

                                   Schedule 2

                             Appointment of expert

1. Pursuant to Clause 5.3, Royal Free may serve notice on Bioenvision ("Referral
Notice") that it wishes to refer to an expert (the "Expert") the questions set
out in that Clause.

2. The parties shall agree the identity of a single independent, impartial
expert to determine such questions. In the absence of such agreement within 30
days of the Referral Notice, the questions shall be referred to an expert
appointed by the President of Law Society of England and Wales.

3. 60 days after the giving of a Referral Notice, both parties shall exchange
simultaneously statements of case in no more than 10,000 words, in total, and
each side shall simultaneously send a copy of its statement of case to the
Expert.

4. Each party may, within 30 days of the date of exchange of statement of case
pursuant to paragraph 3 above, serve a reply to the other side's statement of
case of not more than 10,000 words. A copy of any such reply shall be
simultaneously sent to the Expert.

5. The Expert shall make his decision on the said questions on the basis of
written statements and supporting documentation only and there shall be no oral
hearing. The Expert shall issue his decision in writing within 30 days of the
date of service of the last reply pursuant to paragraph 4 above or, in the
absence of receipt of any replies, within 60 days of the date of exchange
pursuant to paragraph 3 above.

6. The Expert's decision shall be final and binding on the parties.

7. The Expert's charges shall be borne equally by the parties.

                                 Page 18 of 20

<PAGE>

                                   Schedule 3
                        Summary of Development programme

Description of project

Draft Timetable

                                 Page 19 of 20
<PAGE>

BioEnvision draft 28.1.99

GENE TRANSFER FOR THE TREATMENT OF LIVER DYSFUNCTION

Rationale. Methods of treating specific genetic diseases by gene therapy have
been proposed. Genetic diseases which have been the subject of preliminary
clinical trials include cystic fibrosis (CF) and adenosine deaminase (ADA)
deficiency. This programme is not concerned with a genetic condition but gene
transfer to treat patients with liver damage and who have undergone partial
hepatectomy or who have extensive liver damage from other causes. This is based
on the finding that a single intramuscular injection of cDNA in a suitable
vector, can be use to introduce proteins such as blood clotting factors, growth
factors and serum albumen which are normally produced by the healthy liver.
These can be expressed systemically until the liver recovers or throughout life.

The common clinical problems due to chronic hepatic insufficiency following
liver disease, damage and resection result in hypoalbuminaemia and deficiency of
certain factors such as growth and blood clotting factors. Factor VIII is
produced by the normal liver and inadequate supplies result haemophilia A which
is a life threatening condition. Sufferers from haemophilia are unable to clot
blood properly at the site of wounds. In addition to the dangers this poses for
the treatment of open cuts, the inability to clot blood properly causes damage
to joints and to internal tissues, e.g. muscle Liver also produces growth
factors such as insulin like growth factor-1 (IGF-1) which is required for the
repair and protection of tissues including the heart. It is also required for
the repair of the damaged liver. Hence its introduction will enhance the ability
of the liver to recover.

Treatment of hypoalbuminaemia can in theory be achieved by infusing serum
albumen but this has to be of high purity and it has a short half life.
Treatment of haemophilia A is possible by the administration of Factor VIII.
Until recently, albumen and factors such as Factor VIII had to be prepared by
concentration of blood donations which is problematic in that the preparations
could be contaminated with infectious agents such as Hepatitis B virus,
Hepatitis C virus HIV and prions which cause spongiform encephalopathies. The
gene for albumen and Factor VIII has been cloned and this has allowed the
production of recombinant Factor VIII that are of higher purity than blood
concentrates. However the administration of exogenous Factor VIII peptide to a
patient is very expensive and repeated doses are required every few days.

It has been reported that plasmid DNA injected into the muscle of rodents and
other mammals is taken up by the cells of such animals but the injected DNA does
not integrate into the cells. The direct transfer of DNA into muscle cells in
this manner has been proposed as a means of somatic gene transfer (Wells and
Goldspink, FEBS Letters 1992, 306;203-205). In order to develop this for use in
supplementing liver function a number of practical difficulties still remain.
Encouraging results have been obtained for expressing albumen as well as
clotting factors systemically by injecting their cDNA in a plasmid vector under
the control of our myosin regulatory elements. We have, somewhat surprisingly,
found that this enables the functional protein to be exported from the muscle
cell, thus permitting delivery of the protein, via the bloodstream, to a desired
site of action. Furthermore, we have found that the use of a muscle specific
promoter provides a steady constitutive level of expression which allows an

<PAGE>

BioEnvision draft 28.1.99

effective amount of protein to be produced.

The propose work involves

1) Making different plasmid constructs which include the appropriate muscle
specific gene regulatory elements in order to obtain appropriate levels of
systemic expression. This includes multimerization of promoter and enhancer
elements to increase expression levels where required.

2) Constructing and testing other types of vectors including the adeno associate
vectors (AAVs) into which our regulatory elements as well as the appropriate
cDNAs will be included.

3) Expression of albumen, clotting factors V11, V111 and XI and IGF will be
assessed in skeletal muscle, blood, liver and germ cells for the different types
of constructs in nude and normal mice that have been subjected to partial
hepatectomy

4) The determination of the duration of expression of the different vectors over
a period of time up to one year and to assess any immune reaction to the vectors
as well as the engineered gene product in normal as well as nude (immune
incompetent) mice.

The duration of the about investigations is expected to be three years after it
should be appropriate to carry out clinical trials using the constructs deemed
most suitable for the treatment of liver dysfunction.

Budget

                                    Year 1      Year 2     Year 3        Total:

Postdoctoral Molecular Biologist    29,824      30,928     32,078      93,830.00
Level 2.

University Technician, Grade C      17,855      17,855     17,855      53,565.00

Materials & Consumables:             8,900       8,767      8,383      26,050.00

Animals & Food                       2,000       2,900      2,000       6,900.00
                                                                        --------
200 male nude mice (MF-1) @
(pound)26.50/mouse.
Maintenance for 10 weeks
average @ 80p/week/mouse
                                                                      180,345.00

Overheads @ 50%                                                        90,172.50
                                                                       ---------<PAGE>

                                                                   EXHIBIT 10.26

                                                Queen Mary and Westfield College
                                                              Research Agreement

This Agreement is made as of the 8th Day of June 1999 between Queen Mary and
Westfield College of Mile End Road, London El 4NS ("College")and Bioenvision Inc
a Delaware Corporation of 30 Old Rudnick Lane, Dover, Delaware 19901, USA with
offices at Trafalgar House, 11 Waterloo Place, London SW1Y 4AU ("Bioenvision")

WHEREAS:

       Stegram Pharmaceuticals Ltd of 44 Broomfield Drive, Billingshurst, Sussex
       RH14 9TM ("Stegram")has secured certain rights in connection with a
       substance known as Trilostane and as Modrenal and its use in
       pharmaceutical preparations ("Products")

       Stegram has granted Bioenvision a licence to manufacture and market
       Products

       The College has expertise in the evaluation of oestrogen receptors

       The College has been conducting a programme of research in support of
       Stegram's plans to develop and market Products ("Programme I")

       Bioenvision wishes the College to continue and expand Programme I in
       support of its plans to manufacture and market Products and wishes the
       results from this further programme of research ("Programme II") to be
       vested in Stegram

       The College is willing to continue and expand Programme I in support of
       Bioenvision's plans to manufacture and market Products

NOW IT IS HEREBY AGREED:

 1.    Definitions

       1.1   Programme II means a programme of research in support of
             Bioenvision's plans to manufacture and market Products which is
             generally described in Appendix 1.

       1.2   Foreground Intellectual Property means all intellectual property
             and results arising from Programme II and Foreground Intellectual
             Property includes any intellectual property arising from Programme
             I and defined as Foreground Intellectual Property in the agreement
             dated 4 July 1997 between the College and Stegram concerning
             Programme I a copy of which is attached to this Agreement for
             reference.

       1.3   Background Intellectual Property means all intellectual property
             existing at the time of this Agreement concerning the Products
             other than intellectual property which has arisen from Programme I
             and defined as Foreground Intellectual Property in the agreement
             dated 4 July 1997 between the College and Stegram concerning
             Programme I a copy of which is attached to this Agreement for
             reference.

                                     1 of 6
<PAGE>

                                                Queen Mary and Westfield College
                                                              Research Agreement

 2.  Programme II

      2.1   Programme II will be directed by Professor G P Vinson (Division of
            Biomedical Sciences) who will be the College's representative for
            all matters concerning Programme II.

      2.2   Should Bioenvision wish to modify Programme II then the College will
            endeavour to incorporate any modification that does not require
            additional resources and should additional resources be required
            then the College will endeavour to make these available subject to
            suitably qualified staff being available and mutual agreement on the
            charges for these resources.

      2.3   Should Professor G P Vinson (Division of Biomedical Sciences) no
            longer be willing to direct Programme II and/or be employed by the
            College then the College will endeavour to appoint a suitably
            qualified successor who is acceptable to Bioenvision and continue
            with Programme II.

      2.4   Should the College and Bioenvision be unable to agree on a successor
            to Professor G P Vinson (Division of Biomedical Sciences) then the
            College will endeavour to assist Bioenvision should it decide to
            make alternative arrangements to continue with Programme II.

 3.  Payments to the College

      3.1   Bioenvision undertakes to pay the College the following sums:

             Commencing on signature of this Agreement the sum of (pound)25,000
             in 4 (four) equal quarterly instalments in respect of consumables
             and laboratory expenses in connection with Objective I of Programme
             II.

             Commencing on the date of appointment 12 (twelve) quarterly
             instalments of (pound)18,750 for services of a Research Assistant
             (Research Assistant I) which includes provision for (pound)2,500
             per quarter for general laboratory services and consumables.

             Commencing on the date of appointment 12 (twelve) quarterly
             instalments of (pound)16,250 for services of a second Research
             Assistant (Research Assistant II) which includes provision for
             (pound)2,500 per quarter for general laboratory services and
             consumables.

      3.2   All payments will be due on presentation of the College's invoice
            and the College reserves the right to add VAT if required to do so.

      3.3   For the avoidance of doubt Bioenvision recognises that the sums
            payable according to this Article 3 are only sufficient to meet the
            estimated labour and direct material costs of Programme II.

      3.4   Should the College become aware that the direct materials costs will
            exceed those provided for in Article 3.1 then it will promptly
            notify Bioenvision of this and the College undertakes not to incur
            any such additional expenditure without the prior approval of
            Bioenvision.

 4.  Reporting

      4.1   The College will provide Bioenvision with quarterly written progress
            reports and a full and complete written report at the end of
            Programme II and Bioenvision agrees that at the request of Stegram
            the College may provide copies of these reports to Stegram.

                                     2 of 6
<PAGE>

                                                Queen Mary and Westfield College
                                                              Research Agreement

      4.2   The College and Bioenvision may discuss experimental results and
            progress of Programme II at reasonable intervals at the request of
            either the College or Bioenvision.

      4.3   At the request of Bioenvision and/or Stegram the College and Stegram
            may discuss experimental results and progress of Programme II at
            reasonable intervals and may do so without reference to Bioenvision.

 5.  Foreground Intellectual Property

      5.1   Bioenvision recognises and understands that under the terms and
            conditions of a separate agreement between the College and Stegram
            all Foreground Intellectual Property is vested Stegram.

 6.  Background Intellectual Property

      6.1   The College has no interest in intellectual property owned and
            possessed by Bioenvision.

      6.2   Except where stated in this Agreement Bioenvision has no interest in
            any intellectual property owned and possessed by the College.

 7.  Publications

      7.1   Bioenvision recognises that the College has a statutory duty to
            freely disseminate results of its research and shall not prevent any
            publication of results arising from Programme II in accordance with
            this duty.

      7.2   Notwithstanding the provisions of Article 7.1 the College undertakes
            to provide Bioenvision and Stegram with a copy of any proposed
            publication and Bioenvision and/or Stegram may require the College
            to delay publication for a period not exceeding six (6) months in
            order to provide adequate time for consideration and protection of
            any intellectual property.

      7.3   No delay required by Bioenvision and/or Stegram according to Article
            7.2 shall prevent Research Assistant II from submitting a thesis for
            examination in accordance with procedures for examination for a
            higher degree of the University of London.

 8.  Use of Results and College Name

      8.1    Except where the information has already been placed in the public
             domain Bioenvision undertakes not to use or publish or authorise
             others to use or publish any information provided by the College
             hereunder or any abstract therefrom in any scientific or
             promotional or marketing or other material in connection with the
             Products without the prior written permission of the College.

      8.2    The College undertakes not to refuse permission according to
             Article 8.1 where the publication as a whole does not distort or
             misrepresent results or views expressed in the original material
             provided to Bioenvision.

      8.3    Nothing in this Agreement shall be interpreted as the College
             endorsing the Products in any way whatsoever.

                                     3 of 6
<PAGE>

                                                Queen Mary and Westfield College
                                                              Research Agreement

      8.4   Nothing in this Agreement shall be interpreted as giving Bioenvision
            or any other party any right or permission to use or to authorise
            others to use the name of the College or its emblem in any way
            whatsoever.

      8.5   Nothing in this Agreement shall be interpreted as giving the College
            or any other party any right or permission to use or to authorise
            others to use the name of Bioenvision or its emblem in any way
            whatsoever.

 9.  Testing of Substances

      9.1   No College employee may authorise the use of any substance in
            clinical trials or any procedures requiring or normally requiring
            ethical or regulatory approval unless specifically stated in writing
            and in accordance with the College's procedures for such approval.

 10. Warranties and Liabilities

      10.1  Bioenvision warrants that at the time of this Agreement it is the
            lawful owner of rights in respect of Products and Background
            Intellectual Property and has permission from Stegram to enter into
            this Agreement.

      10.2  In entering into this Agreement the parties to this Agreement
            recognise and agree that the College is not a party to any agreement
            between Stegram and Bioenvision concerning the subject matter of
            this Agreement.

      10.3  The College will endeavour to undertake Programme II in a
            professional and diligent manner but except in the case of death or
            personal injury arising from negligence of the College accepts no
            liability for any costs or expenses arising from any interpretation
            or reliance that Bioenvision or other parties may place on any part
            of the work product nor offers any warranty that it will solve any
            particular problem.

      10.4  Bioenvision undertakes to indemnify and keep the College indemnified
            against any costs or expenses arising from claims made against the
            College in connection with this Agreement including but not limited
            to any dispute with Stegram or the infringement of any rights of
            others.

 11. Duration and Termination

      11.1  This Agreement shall commence on the date of signature and shall
            terminate three years after the date of the last appointment
            according to Article 3 unless terminated earlier by mutual
            agreement of the parties to this Agreement.

      11.2  Bioenvision recognises that should Research Assistant II register
            for a higher degree of the University of London then the College
            will not agree to any termination that releases Bioenvision from
            its obligations according to Article 3 in respect of Research
            Assistant II.

      11.3  Either Bioenvision or the College may terminate this Agreement
            without further notice should the other party fail to meet its
            obligations under this Agreement and does not remedy any such
            failure within 2 (two) months of receipt of a written request from
            the other party to remedy any such failure.

                                     4 of 6
<PAGE>

                                                Queen Mary and Westfield College
                                                              Research Agreement

      11.4  No termination of this Agreement shall release Bioenvision or the
            College from their obligations according to Articles 5, 7, 8 and 10.

      11.5  No termination of this Agreement shall affect the rights of
            Bioenvision or the College accrued up to up to the date of such
            termination including nor shall release Bioenvision from the
            obligation to make payments according to Article 3 for work carried
            out and/or reasonable commitments made up to the date of such
            termination.

 12.  Assignment

      12.1  Bioenvision shall not assign all or part of its rights or
            obligations under this Agreement to Stegram or any other third party
            without the prior written approval of the College, such approval not
            being unreasonably withheld where the transferee is a properly
            organised and competent body that agrees to accept all of
            Bioenvision's obligations to the College under this Agreement.

      11.2  The College shall not assign all or part of its rights or
            obligations under this Agreement to any third party without the
            prior written approval of Bioenvision, such approval not being
            unreasonably withheld where the transferee is a properly organised
            and competent body that agrees to accept all of the College's
            obligations to Bioenvision.

 12.  General

      12.1  No variation to this Agreement shall be recognised unless agreed to
            in writing by the parties to this Agreement.

      12.2  The parties to this Agreement agree that this Agreement is the sole
            agreement between the parties in connection with the subject matter
            and that this Agreement replaces and supercedes all previous
            agreements and understandings between the parties.

      12.3  This Agreement shall be governed by the laws of England and be
            subject solely to the jurisdiction of English Courts.

AGREED:

Name:              Dr CB Wood                          Dr D J Westlake

Position:             CEO                  Manager Research Grants and Contracts
          -------------------------

Signature: /s/    Dr CB Wood                  /s/    Dr D J Westlake
          -------------------------       -------------------------------------

On behalf of:  Bioenvision Inc                Queen Mary and Westfield College

Date:              14/6/99                                 7/6/99
     ------------------------------       -------------------------------------

                                     5 of 6
<PAGE>

                                                Queen Mary and Westfield College
                                                              Research Agreement

I accept my obligations under this Agreement:

Name:             Professor G P Vinson

Signature:          /s/ G P Vinson
           ---------------------------------

             Division of Biomedical Sciences
            Queen Mary and Westfield College

Date                  7 June 1999
          ---------------------------------

                                     6 of 6
<PAGE>

                                                Queen Mary and Westfield College
                                                              Research Agreement

                                   Appendix 1

                               Research Programme

                                  Programme II

Aim:  to provide rigorous elucidation of the mode of action of trilostane, and
      analogues, on oestrogen receptor function at the molecular/cellular level.

Objectives: (in order of priority)

1.    To establish interactions of trilostane with specific oestrogen receptor
      isoforms.

      Methods:

        (a)Continue IEF separation of receptor isoforms with quantitation of
           tritiated oestradiol binding in the presence and absence of
           trilostane. This will be performed on breast tumour samples now
           available, otherwise rat uterus.
        (b)Confirm actions of trilostane on affinity of oestradiol binding to
           receptor complement, using Scatchard analysis, in presence and
           absence of trilostane, on breast tumour cytosol preparations.

2.    To establish directly whether the interactions observed in objective I
      affect receptor function.

      Method:

      Using an in vitro reporter system, the effect of trilostane on oestrogen
      receptor activity will be measured. Reporter constructs containing either
      the classical estrogen response element or an AP1 site will be incubated
      with oestrogen receptors in the presence or absence of trilostane,
      tamoxifen or both. Transcriptional activity will be assayed to determine
      whether trilostane has its effect at the nuclear level.

3.    To determine the actions of trilostane on breast cancer cell
      proliferation, in the presence and absence of tamoxifen.

      Methods:

        (a)In vitro. Breast cancer cell lines, e.g. MCF 7, ZR 75, etc., will be
           used in culture to establish the effects of trilostane on oestradiol
           induced proliferation in the presence and absence of tamoxifen.
        (b)In vitro. Epithelial cells isolated from primary breast tumours will
           be grown in culture in the presence and absence of trilostane, as for
           (a).
        (c)In vitro. MCF-7 cells in culture will be cultured in the presence of
           tamoxifen to obtain by selection a tamoxifen resistant cell line. Use
           of these cells in culture in the presence or absence of trilostane
           will determine its effects in a situation that replicates that of
           patients who fail to respond to tamoxifen treatment.
        (d)In vivo. Primary breast tumour cells from patients will be
           transplanted into immunodeficient mice. The effects of trilostane on
           tumour growth in the presence and absence of tamoxifen will be
           determined.

 4.   To establish the precise nature of trilostane interaction with oestrogen
      receptor isoforms in the absence of oestrogen, showing more directly to
      which isoforms trilostane binds, and with what affinity.

                                     1 of 2

<PAGE>

                                                Queen Mary and Westfield College
                                                              Research Agreement

Method:

Using tritiated trilostane in IEF and Scatchard analysis of binding
characteristics. By then competing with unlabelled oestradiol this method will
also determine whether trilostane binding is competitive, or allosteric. If the
latter, this would suggest that results obtained under Objective 1 may not
reveal the full extent of trilostane interactions with the receptor, and may
underestimate its possible effects on oestrogen action.

                                     2 of 2

<PAGE>

                                                Queen Mary and Westfield College
                                                              Research Agreement

This Agreement is made this 6th Day of July 1997 between Queen Mary and
Westfield College of Mile End Road, London El 4NS ("College") and Stegram
Pharmaceuticals Ltd of 44 Broomfield Drive, Billingshurst, Sussex RH14 9TM
("Stegram")

 WHEREAS

Stegram has secured certain rights in connection with a substance known as
Trilostane and as Modrenal its use in pharmaceutical preparations ("Products").

Stegram wishes the College to undertake a programme of research in support of
its plans to develop market Products (Programme").

The College has expertise in the evaluation of oestrogen receptors.

The College is willing to undertake a programme of research in support of
Stegram's plans.

NOW IT IS HEREBY AGREED

1. Programme

      1.1   The Programme will be directed by Professor G P Vinson (Department
            of Biochemistry) who will be the College's representative for all
            matters concerning the Programme.

      1.2   The Programme has been agreed with Stegram and for the avoidance of
            doubt is generally described in Appendix 1.

      1.3   The Programme is expected to be completed by the end of May 1998.

2. Payment

      2.1   Stegram undertakes to pay the College the sum of (pound) 10,000 as a
            contribution towards the expenses of the Programme.

      2.2   The payment will be due on signature of this Agreement on
            presentation of the College's invoice and the College reserves the
            right to add VAT if required to do so.

      2.3   Stegram recognises that this sum does not represent the true cost
            of the Programme and that additional costs will be met from other
            College funds.

3. Reporting

      3.l   The College will provide a written report and commentary on
            experimental results at the end of the Programme.

      3.2   The College and Stegram may discuss experimental results and the
            Programme at reasonable intervals.

4. Results, Discoveries and Inventions

      4.l   In the first instance the College shall own all intellectual
            property arising from this Programme ("Foreground Intellectual
            Property") and the College undertakes not to enter into any
            arrangements with third parties in connection with this that are not
            foreseen by this Agreement.

<PAGE>

      4.2   The College shall be responsible for making its staff aware of the
            need for confidentiality and delaying disclosure of results in order
            to apply for such protection of Foreground Intellectual Property
            that it deems necessary and ensuring that the names of inventors and
            claims to invention are properly registered.

      4.3   Should the College decide not to apply for any specific protection
            of Foreground Intellectual Property then it will inform Stegram and
            Stegram may do so in conjunction with the College or otherwise and
            the College will endeavour to assist Stegram in this matter through
            supply of information in its possession, authorising the signing of
            documents, continuing to maintain confidentiality and delaying
            publication.

      4.4   Should Stegram or the College believe Foreground Intellectual
            Property might be used commercially then it will advise the other
            party and the parties will meet to determine the most appropriate
            way to proceed and the contributions of Stegram the College and any
            third party(ies).

      4.5   After reimbursing the College and/or Stegram for expenses incurred
            under Articles 4.2 and/or 4.3 any remaining proceeds shall be
            distributed as follows

                          Third party(ies)   )
                          Stegram            ) according to contribution
                          College            )

      4.6   The College shall be responsible for distributions to its staff and
            students according to its published policy.

      4.7   The College and Stegram will endeavour to reach mutual agreement
            under Articles 4.4 and 4.5 and shall first refer any dispute to a
            mutually acceptable party and failing resolution shall refer the
            dispute to an arbitrator appointed by the President for the time
            being of the Royal Society of Chemistry whose decision shall be
            binding on both parties.

5. Background Intellectual Property

      5.1   At the commencement of this Agreement Stegram shall be deemed to be
            the owner of all existing intellectual property concerning the
            Products and applications concerning breast cancer ("Background
            Intellectual Property").

      5.2   Should Stegram enter into negotiations with third parties with a
            view to sale or transfer of its interest in or to granting a licence
            for use of part or all of Background Intellectual Property then
            Stegram will promptly advise the College of any such negotiations
            and keep the College informed as to their progress.

      5.3   Before Stegram concludes any negotiations it will meet with the
            College and determine the contribution, to that date, of Stegram and
            the College to any enhancement of the value of the Products and
            Background Intellectual Property brought about by access to
            Foreground Intellectual Property.

      5.4   The parties recognise and accept that Stegrams obligations under
            Articles 5.2 and 5.3 shall exclude negotiations with any third party
            already having a licence from Stegram in connection with the
            Products unless these involve Foreground Intellectual Property and
            use of the Products in connection with breast cancer.

      5.5   The enhancement in value shall be divided between the College and
            Stegram by reference to the respective contributions agreed
            according to Article 5.3.

<PAGE>

      5.6   The College shall be responsible for distribution of its share of
            any enhancement in value to its staff according to its published
            policy.

      5.7   The College and Stegram will endeavour to reach mutual agreement
            under Articles 5.3 and 5.4 and shall first refer any dispute to a
            mutually acceptable party and still failing resolution shall refer
            the dispute to an arbitrator to be appointed by the President for
            the time being of the Royal Society of Chemistry whose decision
            shall be binding on both parties.

6. Publications

      6.1   Stegram recognises that the College has a statutory duty to freely
            disseminate results of its research and shall not prevent any
            publication of results arising from this Programme in accordance
            with this duty.

      6.2   Notwithstanding the provisions of Article 6.1 the College undertakes
            to provide Stegram with a copy of any proposed publication and
            Stegram may require the College to delay publication for a period
            not exceeding six (6) months in order to provide adequate time for
            consideration and protection of any intellectual property.

7. Use of Results and College Name

      7.1   Stegram undertakes not to use or publish or authorise others to use
            or publish any information or results provided by the College
            hereunder or any abstract therefrom in any scientific or promotional
            or marketing or other material in connection with the Products
            without the prior written permission of the College.

      7.2   The College undertakes not to refuse permission where the
            publication as a whole does not distort or misrepresent results or
            views expressed in the original material provided to Stegram.

      7.3   Nothing in this Agreement shall be interpreted as the College
            endorsing or being associated with the Products in any way
            whatsoever.

      7.4   Nothing in this Agreement shall be interpreted as giving Stegram any
            right or permission to use or to authorise others to use the name of
            the College or its emblem in any way whatsoever.

8. Testing of Substances

      8.l   No College employee may authorise the use of any substance in
            clinical trials or any procedures requiring or normally requiring
            ethical or regulatory approval unless specifically stated in writing
            and in accordance with the College's procedures for ethical
            approval.

9. Warranties and Liabilities

      9.1   The College will endeavour to undertake the Programme in a
            professional and diligent manner but accepts no liability for any
            costs or expenses arising from any interpretation or reliance that
            Stegram or other parties may place on the work product nor offers
            any warranty that it will solve any particular problem.

      9.2   Stegram undertakes to indemnify the College against any costs or
            expenses arising from this Agreement including but not limited to
            any dispute concerned with Stegram's rights in the Products or the
            infringement or any rights of others.

<PAGE>

10. General

      10.1  This Agreement shall be governed by the laws ot England and be
            subject solely to the jurisdiction of English Courts.

AGREED

Name:              G Margetts                             Dr D J Westlake
           ------------------------------

Signature: /s/     G Margetts                   /s/     Dr D J Westlake
           ------------------------------       --------------------------------

On behalf of  Stegram Pharmaceuticals Ltd       Queen Mary and Westfield College

Date                  9/7/97                                 4/7/97
           ------------------------------       --------------------------------

I accept my obligations under this Agreement

Name:          Professor G P Vinson
           -----------------------------

Signature: /s/     G P Vinson
           -----------------------------

           Department of Biochemistry

        Queen Mary and Westfield College

Date              7 July 1997
     -----------------------------------

<PAGE>

                                   Appendix 1

                               Research Programme

Purpose

      To determine the interactions of trilostane (Modrenal) with oestrogen
      receptor isoforms in the uterus and in breast tumours.

Objectives

      We will use ligand binding and gel electrophoretic fractionation, as
      appropriate, to characterise oestrogen receptor proteins in human uterus,
      and breast tumours.

      We will use breast tissue obtained at operation, and endometrial samples
      from women of known reproductive status and stage of the menstrual cycle,
      undergoing hysterectomy for benign conditions.

      Cytosols from these tissues will be prepared as described in our
      publications*, incubated with radioactively labelled oestradiol, and
      specifically bound fractions will be separated on isoelectric focusing
      gels to separate the four oestrogen receptor subtypes. Quantitation of
      radiolabelled oestrogen bound to each isoform will be by liquid
      scintillation counting of gel slices.

      Ten samples of each tissue type will be used, and in each case,
      specifically labelled oestradiol will be "competed" with (i) unlabelled
      oestradiol (ii) tamoxifen (iii) Modrenal at varying concentrations.

Expected Results

      The data are expected to show the relative affinities of the oestrogen
      isoforms present in the two tissue types for oestradiol, tamoxifen and
      Modrenal. In particular they are expected to reveal whether the
      anti-cancer efficacy of Modrenal may be associated with binding to one or
      more of the 4 oestrogen receptor subtypes that may be present.

   *V.A. Baker, J.R. Puddefoot, S. Marsigliante, S. Barker, A.W. Goode and G.
      P. Vinson, (1992). Oestrogen receptor isoforms, their distribution and
      relation to progesterone receptor levels in breast cancer samples. Brit.
      J. Cancer. 66. 1083-1087.

   J.R. Puddefoot, V.A. Baker, B. Bakkers, S. Marsigliante, S. Barker, C.
      Panahy, A.W. Goode, R. Carpenter and G.P. Vinson, (1993). The nature
      and significance of multiple isoforms of the oestrogen receptor in breast
      tumours. J. mol. endocr., II. 83-90.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]